可以清除HCV感染吗?

Same author

Introduction of the second-generation direct-acting antivirals (DAAs) in chronic hepatitis C: a register-based study in Sweden.

European journal of clinical pharmacology·2018

Same author

Cirrhosis, high age and high body mass index are risk factors for persisting advanced fibrosis after sustained virological response in chronic hepatitis C.

Journal of viral hepatitis·2018

Same author

Activated Cellular Immunity in Chronic Hepatitis C.

Hematology (Amsterdam, Netherlands)·2016

Same author

Incidence and outcome of Staphylococcus aureus endocarditis--a 10-year single-centre northern European experience.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2015

Same author

Long-term follow-up of successful hepatitis C virus therapy: waning immune responses and disappearance of liver disease are consistent with cure.

Alimentary pharmacology & therapeutics·2015

Same author

Evolution of fibrosis during HCV recurrence after liver transplantation--influence of IL-28B SNP and response to peg-IFN and ribavirin treatment.

Journal of viral hepatitis·2013

Same journal

Rethinking anticoagulation intensity during extracorporeal membrane oxygenation.

Lancet (London, England)·2026

Same journal

Standard-dose unfractionated heparin versus low-dose unfractionated heparin and low-molecular-weight heparin in extracorporeal life support (RATE): an open-label, randomised, non-inferiority trial.

Lancet (London, England)·2026

Same journal

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Lancet (London, England)·2026

Same journal

Documenting hospice care.

Lancet (London, England)·2026

Same journal

After the wood chipper.

Lancet (London, England)·2026

Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026

相关实验视频

可以清除HCV感染吗?

相关概念视频

Introduction of the second-generation direct-acting antivirals (DAAs) in chronic hepatitis C: a register-based study in Sweden.

Cirrhosis, high age and high body mass index are risk factors for persisting advanced fibrosis after sustained virological response in chronic hepatitis C.

Activated Cellular Immunity in Chronic Hepatitis C.

Incidence and outcome of Staphylococcus aureus endocarditis--a 10-year single-centre northern European experience.

Long-term follow-up of successful hepatitis C virus therapy: waning immune responses and disappearance of liver disease are consistent with cure.

Evolution of fibrosis during HCV recurrence after liver transplantation--influence of IL-28B SNP and response to peg-IFN and ribavirin treatment.

Rethinking anticoagulation intensity during extracorporeal membrane oxygenation.

Standard-dose unfractionated heparin versus low-dose unfractionated heparin and low-molecular-weight heparin in extracorporeal life support (RATE): an open-label, randomised, non-inferiority trial.

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Documenting hospice care.

After the wood chipper.

Assisted dying and the silencing of medicine's next generation.

相关实验视频

可以清除HCV感染吗?

相关概念视频

相关文章

Introduction of the second-generation direct-acting antivirals (DAAs) in chronic hepatitis C: a register-based study in Sweden.

Cirrhosis, high age and high body mass index are risk factors for persisting advanced fibrosis after sustained virological response in chronic hepatitis C.

Activated Cellular Immunity in Chronic Hepatitis C.

Incidence and outcome of Staphylococcus aureus endocarditis--a 10-year single-centre northern European experience.

Long-term follow-up of successful hepatitis C virus therapy: waning immune responses and disappearance of liver disease are consistent with cure.

Evolution of fibrosis during HCV recurrence after liver transplantation--influence of IL-28B SNP and response to peg-IFN and ribavirin treatment.

Rethinking anticoagulation intensity during extracorporeal membrane oxygenation.

Standard-dose unfractionated heparin versus low-dose unfractionated heparin and low-molecular-weight heparin in extracorporeal life support (RATE): an open-label, randomised, non-inferiority trial.

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Documenting hospice care.

After the wood chipper.

Assisted dying and the silencing of medicine's next generation.